Combination Drugs for Treating Obesity

Abstract

Although obesity is a chronic disease like hypertension and diabetes, obesity is not treated with drug combinations as are other chronic diseases. This is because orlistat and sibutramine, the two drugs approved for long-term treatment of obesity, do not result in additive weight loss when combined. This article discusses the history of combination drug therapy for treating obesity, the lessons learned from that experience, and describes the drug combinations now in development. One combination of two standardized dietary herbal supplements that result in clinically significant weight loss is also described. Obesity is poised to enter the era of combination drug therapy, as is now the routine in the treatment of other chronic diseases like hypertension and diabetes. The advent of combination drug therapy for obesity treatment offers hope for increasing the efficacy of obesity pharmacotherapy.

A review on phytochemical and pharmacological aspects ofCissus quadrangularisL.

“…This might prove helpful to use its immense therapeutic efficacy as a potent phytomedicine. [26] Anti-inflammatory [27][28][29] Osteoblastogenesis [30] Increases mineralization [31] Increases alkaline phosphatase activity [30] Restore the biomechanical properties and structure of the bone [32,33] Anti-tumor properties [34,35] Analgesic properties [27,29,36] Reduce body weight [37][38][39] Reduce blood glucose levels and serum lipids [40] Alleviating insulin resistance [41] Gastroprotective [42,43] Hepatoprotective [44] Suppresses chronic ulcers [45,46] Antihemorrhoidic activity [27] Antioxidant [47,48] Antiosteoporotic activity [49] Antibacterial [50][51][52][53][54] Antiprotozoal [55] Antiplasmodial [56] Antiviral activity [57] Antipyretic activity [36] Antifungal activity [52,53] CNS activity depressor [58] Anticonvulsant properties [59] …”

Regulatory and policy issues for T1DM immunotherapy

“…This is slowly changing, particularly in areas that have been resistant to monotherapy approaches, obesity being probably the most relevant example. 27 An example of a co-developed investigational combination drug product approved by the same FDA division that regulates diabetes products is Mecasermin rinfabate (iPlex, Insmed Inc.). This product consists of insulin-like growth factor (IGF-1) and its plasma binding protein, IGF-binding protein-3 (IGFBP-3).…”

Phentermine and topiramate combination for chronic weight management: a review

“…6 Hence, combination pharmacotherapy that targets multiple pathways regulating energy homeostasis will achieve more robust and sustained weight loss, especially in complicated obesity. 7 Rational drug combination therapy may also have improved safety and tolerability. Search for novel therapies has led to the development of combination of phentermine and topiramate extended release.…”